FIELD: medicine.
SUBSTANCE: invention relates to medicine. Disclosed is the use in therapeutically effective amounts and ratios of two drugs in COVID-19 combination therapy (SARS-CoV-2). One of these drugs includes aprotinin. The other one includes favipiravir which is SARS-CoV-2 replication inhibitor.
EFFECT: invention provides a synergetic effect of two drugs in treatment of COVID-19 and can significantly reduce the duration of treatment and risk of adverse side effects.
1 cl, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COVID-19 (SARS-COV-2) COMBINATION THERAPY AND TREATMENT METHOD | 2020 |
|
RU2745986C1 |
| PHARMACEUTICAL KIT FOR COMBINATION THERAPY OF COVID-19 (SARS-COV-2) AND METHOD OF ITS APPLICATION | 2020 |
|
RU2746161C1 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| ANTI-SARS-CoV-2-VIRAL PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 2020 |
|
RU2764444C1 |
| ANTI-COVID-19 (SARS-COV-2) VIRAL PHARMACEUTICAL COMPOSITION | 2020 |
|
RU2731932C1 |
| METHOD FOR TREATING PATIENTS WITH HIV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES WITH MODERATE AND SEVERE COVID-19 | 2022 |
|
RU2793414C1 |
| METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
| ANTICORONAVIRUS THERAPEUTIC AGENT - SUBSTITUTED 7-HYDROXY-3,4,12,12A-TETRAHYDRO-1H-[1,4]OXAZINO[3,4-C]PYRIDO[2,1-F][1,2,4]TRIAZINE-6,8-DIONE FOR THE PREVENTION AND TREATMENT OF COVID-19 | 2020 |
|
RU2745985C1 |
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
